Date de publication: 12 juillet 2007
Promoteur – Intermédiaire Financier
Global Health Care GroupLieu
Description
European R&D site(s) of the promoter.
Objectifs
The project comprises the promoter’s ongoing R&D programme 2007-2009 and includes expenditures incurred in the promoter’s European facilities for internal personnel and other operating costs as well as expenses for clinical trials, cooperation, licences, patent registration and laboratory equipment.
Commentaires
This RDI project, encompassing leading R&D in biopharmaceutical and in medical devices aims at the development of innovative therapies and products targeting life-threatening diseases.
Secteur(s)
Montant BEI envisagé (montant approximatif)
EUR 150 million.
Coût total (montant approximatif)
EUR 415 million.
Aspects environnementaux
RDI activities will not materially change current RDI practice and will be carried out within existing facilities, making use of existing laboratories, pilot plants, clinical centres, etc. An EIA therefore is not required by EU Directive 97/11.
Passation des marchés
The promoter is a private company not operating in the Utilities sector, and is thus not covered by EU Directives on procurement.
Statut
Signé - 28/08/2009